SLStephan Lindner

Stephan Lindner

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephan Lindner has a total of 104 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Opioid use disorder medication treatment in residential settings increased 2017-2021, but sustaining it following stays remains an issue

    by Stephan R Lindner, Brynna Manibusan, Kyle Hart, Dennis McCarty, Daniel Hartung, K John McConnell

    Introduction: Residential treatment is part of the care continuum for opioid use disorder (OUD). However, use of OUD medications (MOUD) has been historically low in this setting. The goal of this study was to assess changes in MOUD during residential treatment stays and the 12-month period surrounding them. Methods: We used national Medicaid claims data for the year 2017-2021 and descriptive as well as regression analyses. Results: Between 2017 and 2021, the rate of MOUD treatment in residential settings increased from 30.4 to 58.5 percentage points. By contrast, the rate of MOUD treatment 6 months before residential treatment stays and 5 months following residential treatment stays was low in 2017 and increased only slightly. Changes were similar in states that implemented a substance use disorder waiver compared to non-waiver states. Most states exhibited similar changes. New York was the only state where MOUD rates before and after residential treatment stays increased markedly. Conclusions: Our study suggests that use of MOUD during residential treatment stays increased substantially 2017-2021, but that this increase was not sustained during the months following stays. Improving retention in MOUD treatment following residential treatment stays could be an important future policy goal.

  • Open Access

    Postpartum contraception receipt among Oregon Medicaid-funded births with stimulant and substance use disorder

    by Stephan R. Lindner, Menolly Kaufman, Ann Martinez Acevedo, Deborah J. Cohen

    To compare postpartum contraceptive receipt among (i) Medicaid beneficiaries with stimulant-related substance use disorder (SUD) to those without SUD; and

  • State Proposed Strategies to Expand Access to Medications for Opioid Use Disorder

    by Andrea Baron, Jennifer D. Hall, Jordan Byers, Stephan Lindner, Deborah J. Cohen

    Objective: To identify state strategies to increase access to medications for opioid use disorder (MOUD) through Section 1115 Substance Use Disorder waivers. Study Setting and Design: We conducted a qualitative analysis of 27 waiver applications that were implemented between 2015 and 2020. We identified barriers and proposed strategies for expanding MOUD access and utilization. Data Sources and Analytic Sample: After excluding five states due to insufficient information, we analyzed 22 applications. Principal Findings: We identified six barriers and eight corresponding strategies. Barriers included care delays, limited MOUD facilities, lack of care transition support, limited MOUD access in residential treatment, insufficient care coordination, and prescriber shortages. Commonly proposed strategies were requiring access to MOUD in residential treatment, which was stipulated by the Centers for Medicare & Medicaid Services, addressing prescriber shortages through education and technical assistance, campaigns to address stigma, and increased reimbursement. Other strategies included changes to prior authorization requirements, efforts to increase the number of facilities that offer MOUD, and changes to improve care transitions. Conclusions: States proposed a variety of strategies to expand access to and use of MOUD. Future research could investigate how these approaches, implemented individually or in combination, are associated with outcome change and impact.

  • How Did Medicaid's 1115 Substance Use Disorder Waivers Increase Medication Treatment for Opioid Use Disorder? Evidence From Eight Waiver States

    by Stephan R. Lindner, Jennifer Hall, Brynna Manibusan, Jordan Byers, Kyle Hart, Andrea Baron, DENNIS McCARTY, K. JOHN McCONNELL, Deborah J. Cohen

    Policy Points: States can use substance use disorder waivers to improve their program, but findings regarding the effects of these waivers on opioid use disorder medication treatment have shown mixed results. This study used a mixed‐methods design to identify strategies that states undertook as part of their waiver and that may have led to increases in the use of methadone or buprenorphine. For methadone, adding coverage, increasing reimbursement rates, and engaging providers and managed care organizations may be effective strategies to increase the use of this medication. In contrast, no consistent strategies were identified for buprenorphine. Context: Starting in 2015, states could apply for section 1115 substance use disorder (SUD) waivers to strengthen their continuum of care for treatment of opioid use disorder (OUD). Prior research found substantial variation in changes to medication use for OUD associated with waiver implementation. The objective of this study was to identify strategies that states undertook as part of their waivers that were associated with increases in methadone and buprenorphine treatment in eight waiver states (Indiana, Louisiana, New Hampshire, New Jersey, Pennsylvania, Virginia, Washington, and West Virginia). Methods: In this mixed‐methods study, we combined quantitative difference‐in‐differences analyses of 2016‐2021 Medicaid data with qualitative analyses of states’ waiver application documents ( N = 8) and interviews ( N = 23) with individuals involved in waiver implementation. Findings: SUD waiver implementation was associated with increased use of methadone in Virginia (estimate: 15.4 percentage points [pp]; p < 0.001), Indiana (estimate: 13.2 pp; p < 0.001), West Virginia (estimate: 9.5 pp; p < 0.001), Louisiana (estimate: 7.2 pp; p < 0.001), and New Jersey (estimate: 4.2 pp; p < 0.05). Qualitative information indicated that these states used a variety of strategies, including adding coverage, increasing reimbursement rates, and engaging providers and managed care organizations. By contrast, we observed limited or no strategies to increase the use of methadone in the other states. SUD waiver implementation was associated with increased buprenorphine prescribing in Pennsylvania (estimate: 5.2 pp; p < 0.001), Washington (estimate: 5.2 pp; p < 0.001), New Hampshire (estimate: 4.4 pp; p < 0.01), Louisiana (estimate: 4.2 pp; p < 0.01), and Indiana (estimate: 4.2 pp; p < 0.01). Qualitative analyses suggested that states with and without increases in this outcome implemented similar changes (e.g., education and training activities). Conclusions: Qualitative findings helped explain state‐level variation in methadone treatment following SUD waiver implementation but not for buprenorphine. Strategies identified in higher‐performing states may offer useful insights for other states aiming to expand access to methadone for OUD.


  • Addressing Psychiatric Bed Capacity: Evidence From Medicaid's Institutions for Mental Disease Waivers for Serious Mental Illness

    by K. John McConnell, Jane M. Zhu, Thomas H. A. Meath, Stephan Lindner

    Objective: To assess whether the adoption of Section 1115 Serious Mental Illness and Serious Emotional Disturbance (SMI/SED) Medicaid waivers was associated with increased bed capacity among freestanding psychiatric hospitals. Study Setting and Design: We used a difference‐in‐differences design to study changes in bed capacity in freestanding psychiatric hospitals across all 50 states and the District of Columbia, comparing states that adopted waivers to those that did not. Data Sources and Analytic Sample: We used data from the National Mental Health Services Survey, Centers for Medicare and Medicaid Services Provider of Service files, and other state‐level datasets from 2014 to 2023. Principal Findings: Freestanding hospitals were responsible for most of the growth of psychiatric inpatient bed capacity over the last 10 years. We found no correlation between the option to pursue an SMI/SED waiver and bed capacity or other measures of mental health needs, including state‐based estimates of SMI prevalence or suicide rates. In our difference‐in‐differences analyses, we found no association between the adoption of SMI/SED waivers and bed capacity in freestanding psychiatric hospitals. For example, our estimate of the association of SMI/SED waivers with changes in beds in psychiatric hospitals that accepted Medicaid was −24 beds per 100,000 Medicaid‐enrolled adults (95% CI: −115, 67). Other specifications and outcome variables yielded similar results. Conclusion: While SMI/SED waivers offer the potential to address psychiatric bed shortages, these waivers alone may not suffice to increase inpatient capacity. Given the low uptake and absence of significant change in bed capacity, SMI/SED waivers may need to be redesigned to meet the growing mental health needs of the Medicaid population.


  • The Impacts of 1115 Medicaid Substance Use Disorder Waivers on Medicaid‐Paid Use of Residential Treatment and Other Types of Services in 20 States

    by Stephan R. Lindner, Kyle Hart, Brynna Manibusan, Kirbee A. Johnston, Dennis McCarty, K. John McConnell

    Objective: To assess the association between the implementation of 1115 Medicaid substance use disorder (SUD) waivers and changes in Medicaid‐paid use of residential treatment and other types of services. Study Setting and Design: We compared 20 states with SUD waivers to 14 non‐waiver states using a staggered difference‐in‐differences design. Primary outcomes were Medicaid‐paid opioid‐use disorder (OUD) related residential treatment stays and length of stay (LOS). Secondary outcomes included admissions and LOS for all‐cause and OUD‐related inpatient stays, psychiatric hospital admissions, emergency department (ED) visits, outpatient visits, and primary care visits. Data Source and Analytic Sample: We used the 2016–2021 Transformed Medicaid Statistical Information System (T‐MSIS) Analytic Files (TAF). The analytic sample included Medicaid enrollees ages 18–64 with OUD. Principal Findings: On average, waiver implementation was associated with an increase in residential treatment stays (estimate: 0.4%; 95% CI: 0.1%–0.7%), OUD‐related inpatient visits LOS (estimate: 0.3 days; 95% CI: 0.0%–0.5%), psychiatric hospital LOS (estimate: 1.0 days; 95% CI: 0.6 days–1.4 days), primary care visits (estimate: 3.0%; 95% CI: 1.2%–4.7%), and OUD‐related primary care visits (estimate: 2.7%; 95% CI: 0.9%–4.4%); and a decline in all‐cause inpatient visits (estimate: −0.9%; 95% CI: −1.9% to −0.0%) and OUD‐related inpatient visits (estimate: −0.8%; 95% CI: −1.6% to −0.0%). Results for psychiatric hospital LOS and OUD‐related primary care visits were sensitive to adjusting for pre‐trends. Among four early‐adopting states (Indiana, Louisiana, New Jersey, Virginia), Medicaid‐paid residential treatment increased 1–4 years following waiver implementation (e.g., 2‐year estimate: 2.8%, 95% CI: 2.5%–3.0%), and inpatient visits declined 1–4 years following waiver implementation (e.g., 2‐year estimate: −3.1%, 95% CI: −3.5% to −2.6%). Conclusions: SUD waivers were associated with a small increase in Medicaid‐paid residential treatment and a decline in inpatient visits across states, with changes being concentrated among early‐adopting states.


  • Open Access

    Comparing States with and without Data Quality Concerns in the Transformed Medicaid Statistical Information System Analytic Files for Medicaid enrollees with Opioid Use Disorder

    by Stephan Lindner, Kirbee Johnson, Kyle Hart, Brynna Manibusan, K John McConnell

    Objective. To assess differences (levels, trends, discontinuities) in nine outcomes in states with and without data quality concerns among Medicaid enrollees with opioid use disorder (OUD) in the Transformed Medicaid Statistical Information System (T-MSIS) Analytic Files (TAF). Data sources and study setting. Secondary analysis of TAF 2016-2020 data; Data Quality (DQ) Atlas. Study design. States were classified into two groups: those with and without at least one TAF data field classified as "high concern" or "unusable." We used linear regressions to compare differences in levels and trends between these groups and conducted separate assessments to assess the prevalence of discrete shifts in outcome measures. Data collection: Administrative data. Principal findings. States with data fields classified as "high concern" or "unusable" had a lower level of methadone treatment compared to other states (estimate: -27.4; p-value: +0.000). Other trend or level differences were not significant. Prevalence of abrupt and large changes were not higher in states with at least one data field classified as "high concern" or "unusable" compared to other states. Conclusions. With the exception of methadone, data quality concerns were not associated with patterns of study outcomes that could negatively affect the validity of cross-sectional or longitudinal research.


  • Effects Of Medicaid Waivers On Use Of Medications For Opioid Use Disorder And Nonfatal Overdoses In 17 States

    by Stephan Lindner, Kyle Hart, Brynna Manibusan, Kirbee A. Johnston, Dennis McCarty, K. John McConnell

    A long-standing policy prohibits the use of federal funds for Medicaid services in Institutions for Mental Diseases (facilities with more than sixteen beds that specialize in mental health or substance use disorder treatment). Beginning in 2015, states could apply for Section 1115 Medicaid waivers, which permit federal funding for Institutions for Mental Diseases services and require improvements in opioid use disorder (OUD) treatment. Using 2016-20 Medicaid data, we compared changes in the use of medications for OUD and nonfatal overdoses in seventeen states with waivers approved during 2017-19 to changes in eighteen states without waivers. Waiver implementation was not associated with improvements in overall medication treatment, buprenorphine and naltrexone prescribing, or rates of nonfatal overdoses among Medicaid enrollees with OUD. Waiver implementation was associated with a 2.3-percentage-point increase in the use of methadone with waiver implementation, as a result of coverage changes, and a 3.7-percentage-point increase in any medication treatment among Medicaid enrollees diagnosed with severe OUD who had an inpatient or residential stay. Our findings suggest that such waivers adopted by states during 2017-19 were not associated with significant improvements in medication treatment or reductions in nonfatal opioid-related overdoses among Medicaid enrollees with OUD. However, they may have moderately improved the use of medication treatment for those with severe OUD.


  • Assumptions and Limitations of the Synthetic Control Method

    by Stephan R. Lindner

    To the Editor In a recent JAMA Psychiatry publication of the effects of drug procession law changes in Oregon and Washington, Joshi et al wrote “Unlike